Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • B- Town’s well known Aesthetic permanent beauty expert Dr Shagun Gupta lauds The Expandables Awards 2023 Business
  • MSU students join the Satyagraha against pollution movement led by Greenman Viral Desai as Paryavaran Senani Press Release
  • An insightful new book from Shradha Agarwal about the makeup industry is released Lifestyle
  • HealthOxide Launches Two New Products for Healthy Hair, Skincare Business
  • Anuj Tosniwal Building Brands with Four Pillars Media Agency Business
  • Ramagya Group launching B2B E-commerce platform Ramagya Mart“ Desh Ka Vyapaar” is the positioning adopted for Ramagya Mart Business
  • “Aayudhara Agrofoods: Providing High-Quality Cold-Pressed Oils For Health-Conscious Consumers” Business
  • SKYEXCH, title sponsor of 6ixty, cricket’s power game – the world’s newest and most exciting cricket format starts from August 24 Press Release

DCGI approves Themis Medicare’s VIRALEX® for Covid-19 treatment

Posted on March 5, 2022 By dsprime 16 Comments on DCGI approves Themis Medicare’s VIRALEX® for Covid-19 treatment

Enhances both innate & adaptive immunity and strengthens body’s immune response to viral infections

March 5: In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild tomoderateCOVID-19 patients.

Viralex® has been found to be effective and well tolerated in mild to moderate COVID-19, in two Randomized Controlled Clinical Trials conducted on 499 Indian patients.

In line with the DCGI’s current approach for approval of medicines for the management of the ongoing pandemic, approval for VIRALEX® (Generic name: Inosinepranobex) is based on the results of the robust phase 2 and phase 3RCTs conducted in India, and the well-established safety profile of the drug.

As per the results of the Phase 3 Randomized, Double-blind, Placebo-controlled Trial, 80.17% of patients treated with VIRALEX® showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group.

(52.38%) among the mild to moderate non-hospitalized COVID-19 patients. Clinical Cure was also significantly higher in the VIRALEX® group as compared to that in the placebo group on day 6 of treatment. There was early improvement and cure from symptoms in patients who received VIRALEX®. This drug was well tolerated by the patients without any serious side effects. The study was conducted during the Delta wave of the pandemic.

Randomized, Double-Blind, Placebo-controlled, Multicentre Trial is considered as the clinical research methodology of the highest global standard for evaluating drugs against diseases. Themis is one of the few companies to submit data from a higher number of patients from RCTs for approval in management of COVID-19.

After detailed deliberation, the drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use of the drug as an add on therapy for treatment of mild and moderate COVID-19.

VIRALEX® would be available on the prescription.

Based on the promising study results, the drug appears to offer immense clinical benefit to the patients in the early stages of COVID-19, thus reducing the load on the healthcare system.

VIRALEX® is an immune modulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body’s defence response to viral infections. In an invitro study initiated by Themis, it showed dose-dependent inhibition of viral replication against SARS-CoV-2 (COVID-19).

According to Themis, VIRALEX® will be manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication will be available in the form of a 500 mg tablet at a much affordable price.

Speaking at the release, Dr. Sachin Patel, Managing Director & CEO of Themis Medicare Ltd. said, “Our endeavor has always been to develop medicines that benefit patients and make healthcare far, far more effective. Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, this is our effort to contribute to the well being of people of India”.

“Due to the frequently mutating trend of the virus, the uncertainties of the pandemic continue. We hope access to effective treatment such as VIRALEX® will offer a much-needed therapeutic solution, and if initiated early in the disease, it would reduce the load on the healthcare system.”

Commenting on the significance of this development, Dr. Ashok Swain, Head Clinical Development, congratulated the entire Themis Medicare Ltd. team for achieving an important milestone of adding this effective medicine with an established safety profile to address the unmet need in the management of the pandemic.

“VIRALEX® is a new ray of hope in these challenging times,” he said.

Dr Raja Dhar, eminent pulmonologist and Director and Head of Department of Pulmonology, C K Birla Hospitals, said “Inosine Pranobexisa drug which enhances host immunity (immune modulatory effect) and can affect viral RNA and hence inhibits growth of several viruses. Phase 3 Double blind RCTs are rarein COVID 19. I am heartened to hear that Themis Medicare has come up with such a trial, which shows early clinical response and shortened period of recovery when used in mild to moderate COVID19 cases. This drug, if successfully used in clinical practice would considerably reduce the burden on healthcare system.

Dr Dhar is also the current Chair of Training and Education Initiatives, Indian Chest Society, and Director of Research and Training, National Allergy Asthma Bronchitis Institute.

With a strong R&D backup, skilled domestic & export teams, and 4 state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs like VIRALEX® for COVID-19…and still counting!

About Themis Medicare Ltd

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma Company specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug-delivery systems, the Company has evolved in to being a formidable layer in the complex generics space.

It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs–1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectables portfolio and develop its NDDS presence.

For more details, please visit: www.themismedicare.com

Business Tags:Business

Post navigation

Previous Post: India’s F1 hopeful, Jehan Daruvala signs exclusive representation agreement with Meraki Sport & Entertainment Pvt. Ltd
Next Post: IFSCA’s officer becomes the first to acquire a passport displaying the famed address of GIFT city, Gandhinagar

Related Posts

  • Aseem Ghavri partners with Ashneer Grover for building the next todu-fodu thing: The Third Unicorn Business
  • JONATHAN MARTÍNEZ – Ace Entrepreneur and personal trainer from Madrid Business
  • BLS International Services Ltd. Registers Operational Revenue of Rs 253.8 Crores for Q4 FY 2021-22, growth of 75.5% compared to Q4 FY 2020-21; Profit After Tax at Rs 35.2 Crores grew by 53.0% compared to Q4 FY 2020-21 Business
  • Mrs. Asmi Amol Pangam gets the Trendsetter 2022 award for making a strong name for herself in the real estate sector Business
  • VertexPlus Technologies brings its IPO on 2nd March 2023 Business
  • 8000+ Enthusiasts Learn About the Future of Options Trading at Indian Options Conclave 4.0 Business

Comments (16) on “DCGI approves Themis Medicare’s VIRALEX® for Covid-19 treatment”

  1. marizon ilogert says:
    October 10, 2022 at 7:17 am

    This website is mostly a walk-by way of for all the info you wanted about this and didn’t know who to ask. Glimpse right here, and also you’ll definitely uncover it.

  2. zmozeroteriloren says:
    November 22, 2022 at 4:23 pm

    I dugg some of you post as I thought they were handy invaluable

  3. еко препарати says:
    December 7, 2022 at 10:14 pm

    Great – I should definitely pronounce, impressed with your web site. I had no trouble navigating through all the tabs and related info ended up being truly simple to do to access. I recently found what I hoped for before you know it at all. Quite unusual. Is likely to appreciate it for those who add forums or something, website theme . a tones way for your client to communicate. Nice task..

  4. NFT Newsstand says:
    December 14, 2022 at 2:37 am

    Good write-up, I’m regular visitor of one’s web site, maintain up the nice operate, and It’s going to be a regular visitor for a long time.

  5. A Beginners Guide to Caring for Anteaters. says:
    December 17, 2022 at 7:16 pm

    Hi, I think your site might be having browser compatibility issues. When I look at your website in Safari, it looks fine but when opening in Internet Explorer, it has some overlapping. I just wanted to give you a quick heads up! Other then that, fantastic blog!

  6. How to Write a Business Plan for a Coffee Percolator (electric) Business says:
    December 17, 2022 at 7:53 pm

    Hey There. I discovered your blog the use of msn. This is a really well written article. I’ll make sure to bookmark it and return to learn more of your useful information. Thanks for the post. I will certainly return.

  7. The Best Places to Drink in Srinagar (India) says:
    December 18, 2022 at 3:36 pm

    I think this is among the most significant info for me. And i’m glad reading your article. But wanna remark on few general things, The web site style is wonderful, the articles is really excellent : D. Good job, cheers

  8. Top Places to renew Wedding Vows in Saint Petersburg (Russia) says:
    December 19, 2022 at 12:31 pm

    I?¦ve recently started a site, the info you provide on this site has helped me greatly. Thanks for all of your time & work.

  9. The Best Places to Study in Bhubaneswar (India) says:
    December 20, 2022 at 2:44 pm

    You are a very intelligent individual!

  10. How to Write a Business Plan for a Containers Made Of Tubular Glass Business says:
    December 23, 2022 at 3:30 am

    I got what you mean ,saved to bookmarks, very nice internet site.

  11. Beginners Guide to Growing Hylocereus (Home & Garden Handbook) says:
    December 23, 2022 at 7:19 pm

    hi!,I like your writing so much! share we communicate more about your article on AOL? I require an expert on this area to solve my problem. May be that’s you! Looking forward to see you.

  12. 10 Ways to Use Bakery Mix (Recipe Book) says:
    December 27, 2022 at 2:32 am

    Have you ever considered creating an ebook or guest authoring on other websites? I have a blog centered on the same subjects you discuss and would really like to have you share some stories/information. I know my visitors would appreciate your work. If you’re even remotely interested, feel free to shoot me an email.

  13. How to Become a Locomotive-crane Operator says:
    December 28, 2022 at 11:53 pm

    I have not checked in here for a while as I thought it was getting boring, but the last several posts are good quality so I guess I will add you back to my everyday bloglist. You deserve it my friend 🙂

  14. obstetra em ipanema rj says:
    December 29, 2022 at 1:09 pm

    Maravilha poder usufruir deste conteúdo neste site. Também temos conteúdos relacionados com este em nosso site. Basta acesssar nosso link!

  15. The Best Places to Go for New Years Eve in Jianyang (China) says:
    December 31, 2022 at 9:15 am

    hello!,I like your writing so much! share we communicate more about your post on AOL? I require a specialist on this area to solve my problem. May be that’s you! Looking forward to see you.

  16. why are nfts so expensive says:
    March 2, 2023 at 5:46 am

    Good ?V I should definitely pronounce, impressed with your web site. I had no trouble navigating through all tabs as well as related info ended up being truly simple to do to access. I recently found what I hoped for before you know it at all. Quite unusual. Is likely to appreciate it for those who add forums or something, web site theme . a tones way for your client to communicate. Nice task..

Leave a Reply Cancel reply

Your email address will not be published.

Recent Posts

  • [email protected]: A Vision Plan for a Future-Ready India – KCCI
  • Mr.Nilesh Patil, The First to Introduce a Live Practical Trading Programme in India
  • Dr. Amiti Agrawal: A Visionary IVF Consultant & Endoscopic Surgeon Transforming Fertility Care and Women’s Health
  • Sree Metaliks’ SAANCHI Initiative Launches Mission to Improve Women’s Health and Expand Menstrual Hygiene Awareness in Odisha
  • Film-E-Life! Make Your Life a Blockbuster

Recent Comments

  • يلاشوت on Ace of Spades PR Agency: Who Should Get Published in the Press?
  • Yaiadj on Metta Social gets launched to manage large-scale social projects of Indian Enterprises
  • Yjnspj on Jar, India’s first micro-savings app, raises $22.6 million in Tiger Global-led Series B funding at over $300 million valuation
  • Marygab on Young Achiever of India, Bhavika Maheshwari is bringing about a change through her Spiritual Speeches.
  • Tjafww on Campus-to-Career Conclave : 15 cities movement that aims to improve the staggering < 45% employability numbers for freshers!
  • Wallnut Building Solutions is launching revolutionary cleaning products for tile & stone, Taps & sanitary, Marble & Stone and for removing Epoxy and paint haze from surfaces Business
  • Kochi Startup ExTravelMoney.Com Aids Indian Students in Saving on International University Fees Business
  • The Announcement of Year by All Home Living: Zero Cost EMI for all AV Lovers Lifestyle
  • Sachamoti Royalratan Sabudana’s new ad campaign launched Business
  • English Browne launches India’s First Complete Protection Sanitary Pad Lifestyle
  • Feeling Minds Organised Gala Certification Ceremony to certify Parenting Experts Press Release
  • Serial Entrepreneur All Set To Revolutionise Sports In India: Sunil Nikhar Press Release
  • Tiny India sets up an outlet for funding and buying profitable startups across India Business

Copyright © 2023 Daily News India.

Powered by PressBook News WordPress theme